⚑Today
✨Today's leadDoctors Complete First Bone Marrow Transplant From Deceased Donor for Non-Malignant Disease🎈For kidsSouth Carolina tract beside wildlife refuge to be permanently conserved🌿NatureFormer ocean liner S.S. United States becomes the world's largest artificial reef⚽SportsLindy Duncan wins her first LPGA title on attempt 222🎨Culture & ideasA Lost Altdorfer Landscape Surfaces After 70 Years Privately HeldπŸ”¬Science & healthPeople who control HIV without treatment may help find a cureπŸ’›KindnessA laid-off man began mowing lawns for free and 2,100 volunteers joinedπŸ›οΈPoliticsLos Angeles bans oil drilling after a decade of neighborhood pressureπŸš€ProgressPhiladelphia repaired a collapsed interstate in 12 days

South Korean firm begins prostate cancer trial with J&J drug

The Korea Herald 5 November 2026 1 min read

In short

  • The first patient was dosed Monday in the Phase 1b/2 JET trial, the company said Thursday.
  • The trial tests GI-102 with pasritamig in metastatic castration-resistant prostate cancer.
  • The trial is global, and the source reports no results yet.

Why it's good news

Metastatic castration-resistant prostate cancer is an advanced form that is hard to treat. The trial has only just begun dosing, so it does not yet show whether the combination works. It is a step toward testing a possible treatment, not a treatment in use.

Advertisement

From The Korea Herald

South Korean biotech firm GI Innovation has administered the first dose in a global clinical trial combining its experimental immunotherapy GI-102 with Johnson & Johnson's prostate cancer drug candidate pasritamig, marking a new step in its efforts to develop treatments for advanced cancer. The company said Thursday that the first patient was dosed Monday in the Phase 1b/2 JET trial, which is evaluating the combination in patients with metastatic castration-resistant prostate cancer, an advanced

Read the full story at The Korea Herald Opens the publisher's site in a new tab.

Ask this story

An AI model answers from the material behind this story only, with a link to the source. Your question is sent to our AI provider and isn't stored. See Privacy.

More like this

Advertisement
AdMobile anchor